Sun Pharma Signs Global Lerodalcibep Licensing Deal

: LIB Therapeutics and Sun Pharma have entered into a global licensing and manufacturing agreement for lerodalcibep, a PCSK9 inhibitor used for the treatment of hypercholesterolaemia and mixed dyslipidaemia. Under the agreement, LIB Therapeutics will receive an upfront payment, potential future milestone payments and royalties based on net sales. The deal expands Sun Pharma’s presence in the cardiovascular and lipid-management segment and adds a potential growth opportunity through a differentiated PCSK9 therapy. Commercial execution, regulatory progress and eventual market uptake will be key factors in determining the financial contribution from the agreement. Stock Commentary: SUNPHARMA: The global licensing and manufacturing agreement strengthens Sun Pharma’s specialty and cardiovascular portfolio. Upfront, milestone and royalty-linked economics provide potential long-term value, while commercialisation and regulatory execution remain key monitorables.